Ankara University Cebeci Hospital

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Bladder cancer1 trial
• Cervical cancer1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 1/21 trial
• Phase 31 trial

Status

• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Daiichi Sankyo1 trial
• Telix Pharmaceuticals (Innovations) Pty Limited1 trial

Running trials

• Recruiting

  The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

  NCT06520345· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source

  Contact: Özlem Üstündağ

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Daiichi Sankyo· Source

  Contact: Principal Investigator

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting